COMP <GO>
RCEL vs DCTH // ENTERPRISE SCALE & MARKET CAP
Avita Medical Inc. (NASDAQ) VS. Delcath Systems Inc. (NASDAQ) • 15-METRIC TALLY: RCEL 2
— DCTH 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RCEL
LAST: $16.71 (+1.27%) • MKT CAP: $516.8M
market-cap
$516.8M
LAST: $14.64 (-1.48%) • MKT CAP: $508.0M
market-cap
$508.0M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCEL VS. DCTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RCEL | DCTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.10% | 86.20% | -4.10 | DCTH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 0.80% | -35.80 | DCTH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.23% | 4.13% | -10.36 | DCTH | /fcf-yield <GO> |
| Operating Margin | -59.40% | 0.80% | -60.20 | DCTH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.20% | -63.20 | DCTH | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 129.10% | -117.60 | DCTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 20.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | DCTH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.2 | 37.3 | +28.87 | RCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $516.8M | $508.0M | $8.8M | RCEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RCEL REV | DCTH REV | RCEL GROSS % | DCTH GROSS % | RCEL FCF | DCTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $71.6M | $85.2M | 82.1% | 86.2% | -$32.2M | $21.0M |
| FY 2024 | $64.3M | $37.2M | 85.8% | 83.4% | -$58.1M | -$19.2M |
| FY 2023 | $50.1M | $2.1M | — | — | -$38.0M | -$31.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCEL // BETA —
DCTH // BETA —